Abstract FRI0182 - Table 1 . Demographic and baseline characteristics (FAS), percentage of RA patients with disease worsening and change in disease measures during 52 weeks follow-up (PPS) Demographics and baseline characteristics INX CT-P13
endpoint was disease worsening according to disease-specific composite measures and/or consensus between investigator/patient leading to major treatment change. Exploratory subgroup analyses examined disease worsening and safety in RA. The primary endpoint was analysed using logistic regression, adjusted for diagnosis and disease duration. Results: Demographics, occurence of disease worsening, change in disease measures and treatment-emergent adverse events (TEAE) were similar (Table) . Serum drug levels for INX and CT-P13 were similar throughout the study ( Figure) Conclusions: Explorative analyses in the NOR-SWITCH study showed similar efficacy, serum drug levels and safety in RA patients switched to CT-P13 as those on continuous INX. The study was not powered to show non-inferiority within each diagnosis. Background: The EULAR recommendations for the management of rheumatoid arthritis (RA) update 2013 contained the following research question: "How good is patient adherence to biological agents and can lack of adherence be related to loss of efficacy?" [1] . Limited studies are published in which adherence of RA patients treated with biological disease-modifying anti rheumatic drugs (bDMARDs) has been assessed. Previous studies regarding adherence of RA patients treated with etanercept did not take into account that patients are instructed to temporarily discontinue bDMARDs therapy during e.g. a serious infection. In addition, etanercept concentrations have never been utilized in determining adherence to etanercept in RA patients. Objectives: The aim of our study was to determine the percentage of nonadherent RA patients treated with etanercept, using etanercept concentrations and patient self-report, and to assess the relationship between adherence and clinical outcome during 52 weeks. Methods: Non-adherence was defined as an etanercept trough concentration <0.1ug/mL at least once and no valid/medical reason to miss an etanercept dose. In this retrospective cohort study patients visited our clinic at baseline and 4, 16, 28, 40 and 52 weeks after initiation of etanercept treatment. At baseline and following visits disease activity score of 28 joints (DAS28) was calculated and blood was drawn to measure etanercept concentrations. During each visit patients were asked if they missed an etanercept dose, at which date and for which reason. Remission was defined as DAS28 <2.6 at least for two consecutive visits. Low disease activity (LDA) was defined as DAS28 <3.2 during a minimal of two consecutive visits. Results: In total 292 patients were included. Mean age was 53 years (SD 12.7), 82% was women and median disease duration was 8 years 
